Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > September 11, 2020
Daily News
September 11, 2020
- Komeito Prods Govt to Tap State Coffers for Coronavirus Vaccinations
September 11, 2020
- MHLW Calls for Smooth Supply of Flu Shots as It Anticipates Surging Demand
September 11, 2020
- Japan to Steadily Collect Info on AstraZeneca Trial Pause: Minister
September 11, 2020
- Nihon Chouzai’s Standard Formulary Service Expands to 17 Therapeutic Classes, Monitor Hospitals Moving to Craft Own Lists
September 11, 2020
- 1st Japanese COVID-19 Patient Enrolled in Global PIII of Ultomiris: Alexion
September 11, 2020
- Enspryng Reduces Risk and Severity of Relapse by 79% in NMOSD Patients: Chugai
September 11, 2020
- Chugai, Takeda to Join Global PIII of Tecentriq/Cabometyx Combo in Japan
September 11, 2020
- Hisamitsu Seeks Label Expansion for Fentos Tape to Pediatric Cancer Pain
September 11, 2020
- MSD Files Keytruda for MSI-H Colorectal Cancer
September 11, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…